YiChang HEC ChangJiang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
YiChang HEC ChangJiang Pharmaceutical has a total shareholder equity of CN¥7.9B and total debt of CN¥2.4B, which brings its debt-to-equity ratio to 30.5%. Its total assets and total liabilities are CN¥12.7B and CN¥4.8B respectively. YiChang HEC ChangJiang Pharmaceutical's EBIT is CN¥2.8B making its interest coverage ratio 16.9. It has cash and short-term investments of CN¥1.7B.
Key information
30.5%
Debt to equity ratio
CN¥2.42b
Debt
| Interest coverage ratio | 16.9x |
| Cash | CN¥1.69b |
| Equity | CN¥7.94b |
| Total liabilities | CN¥4.81b |
| Total assets | CN¥12.74b |
Recent financial health updates
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25
Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13Recent updates
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?
Apr 23YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Financial Position Analysis
Short Term Liabilities: 1558's short term assets (CN¥6.1B) exceed its short term liabilities (CN¥4.3B).
Long Term Liabilities: 1558's short term assets (CN¥6.1B) exceed its long term liabilities (CN¥476.6M).
Debt to Equity History and Analysis
Debt Level: 1558's net debt to equity ratio (9.2%) is considered satisfactory.
Reducing Debt: 1558's debt to equity ratio has increased from 1.5% to 30.5% over the past 5 years.
Debt Coverage: 1558's debt is well covered by operating cash flow (69.2%).
Interest Coverage: 1558's interest payments on its debt are well covered by EBIT (16.9x coverage).